News

On-demand treatment with deucrictibant can help resolve swelling attacks in people with all major forms of hereditary angioedema (HAE), according to top-line data from a Phase 3 clinical trial. Pharvaris, deucrictibant’s developer, plans to use the Phase 3 findings to support a U.S. Food and Drug Administration (FDA)…

Short-term preventive treatment with on-demand Berinert (human C1 esterase inhibitor) immediately before delivery helps women with hereditary angioedema (HAE) avoid swelling attacks during childbirth, according to case series and literature review from Japan. About half of pregnant women with HAE experienced more acute attacks during pregnancy, particularly in…

Long-term treatment with Dawnzera (donidalorsen) — approved in the U.S. earlier this year for people with hereditary angioedema (HAE) — effectively reduced swelling attacks in HAE patients in two clinical trial extension studies, according to new data. The newly reported results were based on data from patients who…

A European Medicines Agency (EMA) committee recommended that Dawnzera (donidalorsen) be approved to prevent swelling attacks in hereditary angioedema (HAE) patients 12 and older. The positive opinion comes from the EMA’s Committee for Medicinal Products for Human Use (CHMP), which is tasked with reviewing safety and efficacy data…

Ekterly (sebetralstat), given as a tablet that dissolves on the tongue, resulted in early, effective, and safe management of swelling attacks in children with hereditary angioedema (HAE) aged 2-11, according to interim data from a clinical trial. The ongoing Phase 3 study, KONFIDENT-KID (NCT06467084), which has enrolled…

While the treatment landscape for people with hereditary angioedema (HAE) has improved significantly in the last decades, symptoms such as uncontrolled swelling attacks — occurring despite the use of on-demand or long-term preventive therapies — have resulted in low health-related quality of life (HRQoL) among patients, particularly women and those with…

A young man in Greece developed acquired angioedema, one of the rarest forms of angioedema, as a complication of Mycoplasma pneumoniae infection — the bacterium best known for causing lung infection, or pneumonia — according to a recent case report. While being treated for pneumonia, the man suddenly…

The first adult participant with hereditary angioedema (HAE) has been dosed in STOP-HAE, a Phase 3 clinical trial evaluating the efficacy of ADARx Pharmaceuticals’ investigational therapy ADX-324. Designed as a long-acting preventive treatment, ADX-324 aims to reduce the frequency of swelling attacks while requiring fewer injections. The…

A man in the U.S. developed nonallergic angioedema on his tongue after he ran out of his blood-pressure medication and took his spouse’s lisinopril, another medication used to lower blood pressure, for two weeks. The man had experienced a swelling episode from lisinopril (brand name Qbrelis, among others), an…

Many patients in Brazil lack access to first-line treatments such as Takhzyro (lanadelumab) to prevent swelling attacks in hereditary angioedema (HAE), a study found. “Despite recent advances, access to first-line therapies for long-term prophylaxis of HAE attacks remains limited,” the researchers wrote. These limitations “may likely be encountered in…